Navigation Links
Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.
Date:7/31/2008

BASINGSTOKE, England and PHILADELPHIA, July 31 /PRNewswire-FirstCall/ -- Shire Limited (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company announces results for the three months to June 30, 2008.
Q2 2008 Financial Highlights

- Product sales up 40% to $706m

- Product sales excluding ADDERALL XR(R) up 64% to $409m

- New product sales(1) $243m, 34% of product sales (2007: 18%)

- Total revenues up 35% to $776m

- US GAAP earnings per ADS: loss $0.44 (2007: loss $9.93)

- Non GAAP earnings per ADS up 70% to $0.95 (2007: $0.56)

- Revenue guidance upgraded - 2008 revenue growth now expected to

be at least 20% (previous guidance: mid to high teens)

(1) New product sales comprise DAYTRANA, ELAPRASE, FOSRENOL, LIALDA /

MEZAVANT and VYVANSE

Angus Russell, Chief Executive Officer, commented:

"Shire continues to deliver strong growth and broaden its business in specialty biopharmaceuticals. Our product sales for the quarter were up 40% on Q2 2007 with sales of new products now comprising 34% of total product sales. At $409m, product sales excluding ADDERALL XR were up 64% reflecting the success of our strategy to build a pipeline and portfolio for Shire's future growth.

"We are pleased with the performance of ELAPRASE, FOSRENOL, LIALDA, REPLAGAL and VYVANSE and are looking forward to the continued growth of VYVANSE in the US supplemented by the recent launch of the adult indication, the additional dosage strengths and the back-to-school season.

"We have decided to commence a phased discontinuation of DYNEPO. Resources supporting this product will be re-directed to faster growing, profitable core global products.

"The proposed acquisition of Jerini AG in Germany, which we expect to complete in Q3, is an excellent match for our business and we expect to benefit from both its near term revenues and long term growth. The recent EU approval of Je
'/>"/>

SOURCE Shire Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... CA (PRWEB) July 14, 2014 ... patient registry platform, announced that three PatientCrossroads-based ... dystrophies; the Phelan-McDermid Syndrome International Registry; and ... Syndrome—have been awarded contracts by the Patient-Centered ... the creation of a new health data ...
(Date:7/13/2014)... discovery 30 years ago of soccer-ball-shaped carbon molecules called ... Now, there appears to be a new ball on ... and Tsinghua University in China have shown that a ... cage similar to a carbon buckyball. It,s the first ... matter of speculationdoes indeed exist. , "This is the ...
(Date:7/13/2014)... Dallas, TX (PRWEB) July 13, 2014 ... Silver Industry” is a professional and in-depth study on ... Global and China. , The report provides a basic ... chain structure. Global market analysis and Chinese domestic market ... trends and competitive landscape of the market. A comparison ...
(Date:7/12/2014)... York (PRWEB) July 12, 2014 ... for various reagents used in the life ... driving the life science reagents market towards ... include manufacturers and providers of life science ... Market Report: http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . , The ...
Breaking Biology Technology:PatientCrossroads Fuels Development of New National Clinical Research Network 2PatientCrossroads Fuels Development of New National Clinical Research Network 3Researchers discover boron 'buckyball' 2Researchers discover boron 'buckyball' 32014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 22014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 3Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3
... of assay of cell-mediated ... immunity, ... data on the monitoring of cell-mediated immunity (CMI) in adult patients,undergoing heart ... demonstrated that ImmuKnow(R) values,appear to closely reflect the immune function of the ...
... REHOVOT, Israel and JERSEY CITY, New Jersey, April ... leader in,the development of microRNA-based diagnostics and therapeutics, ... upcoming annual AACR,conference in San Diego. The posters ... and how they may be applied to develop,objective ...
... Zentaris Inc.,(Nasdaq: AEZS TSX: AEZ;), a global biopharmaceutical ... that David J. Mazzo, Ph.D.,has resigned as President ... the,Board of Directors of AEterna Zentaris, effective immediately. ... of AEterna Zentaris, has been,appointed as the interim ...
Cached Biology Technology:Immune Function in Adult Heart Transplant Patients Reflects Risk for Organ Rejection and Infection 2Immune Function in Adult Heart Transplant Patients Reflects Risk for Organ Rejection and Infection 3Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 2Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 3Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 4Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 5AEterna Zentaris Announces Changes to its Management Team 2
(Date:7/10/2014)... SPRINGS, Colo. , June 27, 2014 /PRNewswire/ ... that the National Institute of Standards and Technology ... 10 of its academic research and forensic science ... (FSSB).  The Board is an element of the ... AAFS members are among the first appointments made ...
(Date:7/10/2014)... -- Aware, Inc. (NASDAQ: AWRE ), a leading ... June 26, 2014 that its Board of Directors had ... or approximately $40 million in total.  The Board established ... payment date of July 24, 2014.  The Company was ... ex-dividend date for this special cash dividend.  An ex-dividend ...
(Date:7/10/2014)... July 2, 2014  Unisys Corporation,s (NYSE: UIS ... Nederland N.V., today announced that it has been selected by ... manage a new Basic Provision Biometrics solution for penitentiaries across ... won the contract with a solution based on its open ... term of the contract is up to seven years, with ...
Breaking Biology News(10 mins):Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3
... Wallace, PhD, a pioneering genetics researcher who founded the ... 2012 Genetics Prize of The Gruber Foundation. Wallace is ... groundbreaking achievements in helping science understand the role of ... and as markers for human evolution., He will receive ...
... , ,Oligonucleotide technologies, such as siRNA, tap into ... efficiently regulate gene expression. As such, they have ... therapeutic options for disease targets previously considered un-druggable ... despite the promise, clinical development has been hindered ...
... a half-dozen palladium- and iron-based catalysts for cleaning up the ... TCE far faster than iron -- up to a billion ... in a new study in the August issue of the ... trichloroethene, is a widely used chemical degreaser and solvent that,s ...
Cached Biology News:$500,000 Gruber Foundation Genetics Prize goes to Philadelphia scientist 2Oligonucleotide Delivery: Biology, Engineering and Development Conference 2Oligonucleotide Delivery: Biology, Engineering and Development Conference 3Palladium-gold nanoparticles clean TCE a billion times faster than iron filings 2
... OA-Hy cis- 9-Octadecenoyl-N-hydroxylamide Oleoyl-N-hydroxylamide ... UNDER INERT GAS. A potent inhibitor of ... (K i = 1.7 μM). ... EtOH or DMSO. Unstable in solution, reconstitute ...
... early protein. Can detect ... exhibiting an intranuclear inclusion staining ... 6-24 hours. These antibodies ... staining. No other nuclear ...
Mouse monoclonal [1241] to Parainfluenza Virus type 2...
Goat polyclonal to DRAK2...
Biology Products: